BIAF Stock Gains As CyPath Sales Surge 146% In Q1

• CyPath uses flow cytometry and AI to provide “likely” or “unlikely” malignancy results.
• Rising pulmonary nodules and lung cancer survivors could drive market revenue to over $560 million.
• bioAffinity’s commercial initiatives include expanding physician sites, peer education, and integration into clinical workflows.

bioAffinity Technologies, Inc. (BIAF) announced on Wednesday that its CyPath Lung test has surpassed sales expectations in the first quarter of 2026, recording a 146% year-over-year increase in unit sales.

CyPath Lung combines flow cytometry with AI to deliver clear “likely” or “unlikely” malignancy results to physicians. Real-world applications suggest the test can detect lung cancer at Stage 1A, improving treatment outcomes, and reduce unnecessary invasive procedures when malignancy risk is low.

Strong Market Demand

Estimates from the U.S. Preventive Services Task Force suggest that indeterminate pulmonary nodules detected in the U.S. will increase 62%, from 2.9 million in 2025 to 4.7 million by 2030. The number of lung cancer survivors is also expected to rise from 680,000 to more than 871,000 over the same period. 

Capturing just 10% of these markets could generate $358 million in revenue for CyPath Lung, growing to over $560 million in five years, driven by a 10% compound annual growth rate fueled by broader screening adoption and AI-enhanced imaging technologies.

“CyPath Lung is designed to address a critical gap in the diagnostic pathway by supporting lung cancer risk assessment, pulmonary nodule management and post-treatment surveillance.”

-Maria Zannes, President and CEO of bioAffinity Technologies

Following the update, bioAffinity stock traded over 8% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory while message volume shifted to ‘low’ from ‘normal’ levels in 24 hours. 

Commercial Strategy Boosts Adoption

bioAffinity has focused on CyPath Lung as its flagship product, expanding ordering sites, promoting peer-to-peer education among pulmonologists, and integrating the test into routine lung cancer risk assessment workflows. 

Revenue for CyPath Lung rose 87% year-over-year in 2025, while test units sold grew 99% compared to 2024.

BIAF stock has gained over 260% year-to-date. 

Also See: MSFT Stock Struggles As Weakest Of Magnificent Seven In Q1 – And Now It Is Spending $5.5B More On AI

For updates and corrections, email newsroom[at]stocktwits[dot]com.